Cyclo Therapeutics (CYTH) Stock Price, News, Quotes-Moomoo

$Cyclo Therapeutics (CYTH.US)$
EditorLina Guerrero
Published 10/08/2024, 05:25 PM
Cyclo Therapeutics, Inc., a biopharmaceutical company, announced today that it has entered into a material definitive agreement with Rafael Holdings, Inc., securing a new convertible promissory note worth $3 million. This agreement amends previous arrangements, extending the maturity date of existing notes and aligning them with the new note's terms.
On ...

Teddy123

Sep 12 06:13

Funding secured

$Cyclo Therapeutics (CYTH.US)$
Cyclo Therapeutics secures $3 million convertible note financing By Investing.com

Teddy123

Sep 5 08:06

Phase 3 data encouraging

$Cyclo Therapeutics (CYTH.US)$
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data From Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (Npc1)
https://www.moomoo.com/t/news/flash/19100681/3FJnV3zjzb

Jaguar8

Sep 5 08:05

NEWS

$Cyclo Therapeutics (CYTH.US)$
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Cyclo Therapeutics (Nasdaq: CYTH) presented encouraging preliminary safety data from its ongoing pivotal Phase 3 study (TransportNPC™) and substudy evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) at the SSIEM Annual Symposium 2024. The TransportNPC™ study, with 104 enrolled pa...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CYTH Cyclo Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target